Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elucidator ctDNA resistance screening during first-line osimertinib for EGFR-mutated non-small cell lung cancer
jRCTs031180051Completed
- Sponsor
- National Hospital Organization
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by National Hospital Organization. Primary endpoint: Incidence and proportion of osimertinib resistance-related genetic mutations in ctDNA. Started May 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180051.